Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website http://www.jocmr.org

Review

Volume 6, Number 2, April 2014, pages 75-85


Levosimendan in Critical Illness: A Literature Review

Table

Table 1. Studies Evaluating the Safety of Levosimendan in Critically Ill Patients
 
StudyDose bolusDose infusionDurationMajor adverse effects
Aidonidis et al. Cardiol Res Pract. 2011 [35]00.05 - 0.2 µg/kg/min72 hNo discontinuations due to adverse effects, two patients died of advanced heart failure.
Follath et al. Lancet. 2002 [38]24 µg/kg0.1 µg/kg/min24 hHypotension, headache, hypokalemia
Kivikko et al. J Clin Pharmacol. 2002 [37]0.05 - 0.1 µg/kg/min7 daysNo major adverse effects, no premature discontinuations
Moiseyev et al. Eur Heart J. 2002 [32]6, 12, 24 µg/kg0.1 - 0.4 µg/kg/min6 hHypotension, myocardial rupture, headache, sinus tachycardia
Poelzl et al. Herz. 2008 [75]6 - 12 µg/kg0.07 - 0.2 µg/kg/min24 hNot reported
Silva-Cardoso et al. Rev Port Cardiol. 2009 [33]12 µg/kg0.05 - 0.2 µg/kg/min24 hHypotension, hypokalemia